Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Company news
>
2023
>
Presented Non-Clinical Summary Data for The Best-in-Class Selective BCL2
Presented Non-Clinical Summary Data for The Best-in-Class Selective BCL2
Read also
ChemDiv Extends CMC Services
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
EGFR Kinase Inhibitors for GFR Mutant Lung Cancer
ChemDiv’s Discovery Platform Enables Differentiated, Reversible Pan EGFR Kinase Inhibitors for GFR Mutant Lung Cancer
ChemDiv Continues R&D Services Support for Clywedog Therapeutics
San Diego, CA — September 30, 2025 — ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry,
ChemDiv Partnership with Mondego Bio
ChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology Program
